KEVIN LAI: Open Payments
NPI 1992134258 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,834 in 77 payments from 20 companies in 2025. Trend: 2023 $1,459 · 2024 $1,668 · 2025 $1,834
Food & beverage: $1,642Education: $191
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $335 |
| TOLMAR, INC. | 13 | $260 |
| Endo USA, Inc. | 9 | $213 |
| Sumitomo Pharma America, Inc. | 11 | $197 |
| Janssen Biotech, Inc. | 7 | $194 |
| IMMUNITYBIO, INC. | 3 | $89 |
| Dendreon Pharmaceuticals LLC | 4 | $74 |
| Ferring Pharmaceuticals Inc. | 3 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $63 |
| Antares Pharma, Inc. | 3 | $53 |
Products named: ERLEADA, XTANDI, XIAFLEX, ELIGARD, JATENZO, ORGOVYX, GEMTESA, ANKTIVA.
Industry payments across MA — which companies pay providers there.
